Retrophin Inc (NASDAQ:RTRX) SVP William E. Rote sold 1,034 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $21.50, for a total value of $22,231.00. Following the sale, the senior vice president now owns 11,156 shares of the company’s stock, valued at approximately $239,854. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Retrophin Inc (NASDAQ:RTRX) opened at $22.75 on Friday. Retrophin Inc has a 1-year low of $15.55 and a 1-year high of $26.44. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15.
A number of brokerages have recently issued reports on RTRX. Zacks Investment Research upgraded Retrophin from a “strong sell” rating to a “hold” rating in a report on Thursday, January 4th. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Finally, ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $44.00.
Several hedge funds have recently modified their holdings of RTRX. Alliancebernstein L.P. boosted its stake in shares of Retrophin by 104.1% in the second quarter. Alliancebernstein L.P. now owns 98,020 shares of the biopharmaceutical company’s stock valued at $1,901,000 after buying an additional 50,000 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Retrophin by 1.0% in the second quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 290 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Retrophin by 14.6% in the second quarter. Nationwide Fund Advisors now owns 59,424 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 7,583 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Retrophin in the second quarter valued at approximately $279,000. Finally, Northern Trust Corp boosted its stake in shares of Retrophin by 3.8% in the second quarter. Northern Trust Corp now owns 708,248 shares of the biopharmaceutical company’s stock valued at $13,732,000 after buying an additional 26,119 shares during the period.
TRADEMARK VIOLATION NOTICE: This article was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/02/18/retrophin-inc-rtrx-svp-sells-22231-00-in-stock.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.